Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

nizhpharm jsc - glycerol - suppositories rectal - 1,24g

European Union - English - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

European Union - English - EMA (European Medicines Agency)

pacira limited - cytarabine - meningeal neoplasms - antineoplastic agents, - intrathecal treatment of lymphomatous meningitis. in the majority of patients such treatment will be part of symptomatic palliation of the disease.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - multiple sclerosis - other nervous system drugs - fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (expanded disability status scale 4-7).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethyl fumarate - multiple sclerosis - immunosuppressants - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferon beta-1a - multiple sclerosis - immunostimulants, - treatment of relapsing remitting multiple sclerosis in adult patients.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple sclerosis - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

European Union - English - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - multiple sclerosis - immunosuppressants - zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (rms).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen sodium - muscular atrophy, spinal - other nervous system drugs - spinraza is indicated for the treatment of 5q spinal muscular atrophy.